Welcome to our dedicated page for Protagenic Therapeutics news (Ticker: PTIX), a resource for investors and traders seeking the latest updates and insights on Protagenic Therapeutics stock.
Protagenic Therapeutics Inc (PTIX) is a clinical-stage biopharmaceutical company developing novel peptide-based therapeutics targeting stress-related neuropsychiatric and mood disorders. This page serves as the definitive source for official company updates, providing investors and researchers with timely access to validated information about PTIX's scientific advancements and operational developments.
Visitors will find curated press releases covering clinical trial progress, regulatory milestones, research publications, and strategic partnerships. Key focus areas include updates on lead candidate PT00114 – a synthetic TCAP analog designed to modulate stress response systems – along with pipeline developments in anxiety, depression, and PTSD therapeutics.
The resource prioritizes factual reporting on preclinical studies, IND submissions, trial phase transitions, and peer-reviewed data disclosures. Content is organized to highlight material events while maintaining compliance with financial disclosure standards. Regular updates ensure stakeholders can track the company's progress in advancing peptide-based CNS therapies through clinical validation stages.
Bookmark this page for direct access to Protagenic Therapeutics' latest announcements, or subscribe to receive email alerts when new developments occur in this innovative neurotherapeutic research space.
Protagenic Therapeutics (Nasdaq:PTIX) announced a 1-for-4 reverse stock split effective March 23, 2023, to comply with Nasdaq's minimum bid price requirement. This decision follows shareholder approval on November 23, 2022. The reverse split will convert every four shares into one, reducing the outstanding shares from approximately 17.3 million to about 4.3 million. All stockholders will be uniformly affected, and no fractional shares will be issued. The aim is to increase the stock price above $1.00 for continued listing. Comprehensive details are available on the company’s website and SEC filings.
Protagenic Therapeutics (NASDAQ:PTIX) announced its participation in the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference set for April 27, 2022, at 10:30 AM ET. The biopharmaceutical company, focused on treating stress-related neurologic disorders, will present on its pre-clinical drug candidates. Investors interested in the conference can access the presentation via this link. For further inquiries or to schedule one-on-one meetings, attendees are encouraged to contact their conference representative.
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) reported its Q3 2021 results, highlighting significant advancements in developing PT00114 for stress-related neurological disorders. The company hosted a virtual science review and KOL webinar, discussing PT00114's potential for treating depression, anxiety, PTSD, and addiction. Financially, net loss decreased to approximately $0.9 million from $1.0 million year-over-year, with R&D expenses also down at $0.3 million. The company holds $10.8 million in cash and plans to refile its IND application in Q4 2021, with a Phase I/IIa study set for Q1 2022.
FAQ
What is the current stock price of Protagenic Therapeutics (PTIX)?
What is the market cap of Protagenic Therapeutics (PTIX)?
